Duke University oncologist Amy Abernathy says the policy shift towards more comparative effectiveness research presents some problems for researchers doing work in cancer, reports Scientific American's Katherine Harmon. The first problem, Harmon writes in the Observations blog, is that comparative effectiveness research focuses on broad populations of patients, but that oncology is about individual treatment.